Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Circulating PCSK9 has been associated with increased platelet reactivity and adverse outcomes in patients with atherosclerotic cardiovascular disease.
However, the relative effects of additional PCSK9 inhibitions on platelet reactivity in patients on DAPT and chronic statin therapy has not been evaluated.
To answer this gap in knowledge, we performed a collaborative individual patient data meta-analysis of randomized controlled trials finding that, although PCSK9 inhibitors significantly reduced circulating lipoproteins, such reduction did not translate into any significant change in platelet reactivity at 4 weeks.
These results suggest that the effects of PCSK9 inhibitors are mostly related to plaque stabilization rather than an off-target effect on platelets.”
Read the full article here.
Article: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies
Authors: Luis Ortega-Paz, Yasushi Ueki, Claudio Laudani, Sylvain Losdat, Francesco Franchi, Ryota Kakizaki, Fabiana Rollini, Jonas Häner, Lorenz Räber, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists
-
Aug 21, 2026, 13:51Join EHC 2026 Annual Conference
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency